Show simple item record

dc.contributor.authorPavlidis, Nicholasen
dc.contributor.authorNikolaides, C.en
dc.contributor.authorAthanasiades, A.en
dc.contributor.authorBeriatou, K.en
dc.contributor.authorSkarlos, Dimosthenis V.en
dc.contributor.authorGiannakakis, T.en
dc.contributor.authorKosmidis, Paraskevas A.en
dc.contributor.authorKarvounis, N.en
dc.contributor.authorFountzilas, Georgeen
dc.creatorPavlidis, Nicholasen
dc.creatorNikolaides, C.en
dc.creatorAthanasiades, A.en
dc.creatorBeriatou, K.en
dc.creatorSkarlos, Dimosthenis V.en
dc.creatorGiannakakis, T.en
dc.creatorKosmidis, Paraskevas A.en
dc.creatorKarvounis, N.en
dc.creatorFountzilas, Georgeen
dc.date.accessioned2018-06-22T09:54:20Z
dc.date.available2018-06-22T09:54:20Z
dc.date.issued1996
dc.identifier.urihttps://gnosis.library.ucy.ac.cy/handle/7/42310
dc.description.abstractPreclinical data have shown a synergism between 5-fluorouracil and interferon-γ against human colon carcinoma cell lines. We conducted a phase II trial of this combination in 34 patients with metastatic colorectal cancer. 5-Fluorouracil was administered as an intravenous bolus of 500 mg/m2 weekly and interferon-γ subcutaneous injection at a dose of 200 μg (6 × 106 IU) 3 times a week. Thirty-two patients were evaluable for response. There was one complete and two partial responses (response rate 9.0%, 95% CI 1.98–25.02%). Eleven patients (34%) had stable disease. Common toxicities included fever 81%, nausea/vomiting 19%, diarrhea 16%, flu-like syndrome 16%, malaise 12.5% and leukopenia 12.5%. These results indicate that the above combination of 5-fiuorouracil and interferon-γ has an unimpressive activity in patients with advanced colorectal carcinoma. Toxicity was very tolerable. © 1996 S. Karger AG, Basel.en
dc.language.isoengen
dc.sourceOncology (Switzerland)en
dc.subjectInterferon-γel
dc.subjectArticleen
dc.subjectAntineoplastic agenten
dc.subjectFluorouracilen
dc.subjectHumanen
dc.subjectHumansen
dc.subjectAdulten
dc.subjectFemaleen
dc.subjectMiddle ageden
dc.subjectCancer combination chemotherapyen
dc.subjectPriority journalen
dc.subjectAnemiaen
dc.subjectAntineoplastic combined chemotherapy protocolsen
dc.subjectClinical articleen
dc.subjectClinical trialen
dc.subjectDiarrheaen
dc.subjectLeukopeniaen
dc.subjectNeutropeniaen
dc.subjectPhase 2 clinical trialen
dc.subjectProspective studiesen
dc.subjectThrombocytopeniaen
dc.subjectTreatment outcomeen
dc.subjectAntineoplastic activityen
dc.subjectFeveren
dc.subjectMetastasisen
dc.subjectNeoplasm metastasisen
dc.subjectColorectal canceren
dc.subjectGamma interferonen
dc.subjectInterferon type iien
dc.subjectMalaiseen
dc.subjectMaleen
dc.subjectIntravenous drug administrationen
dc.subjectSubcutaneous drug administrationen
dc.subjectVomitingen
dc.subjectColorectal neoplasmsen
dc.subjectDrug toleranceen
dc.subjectNauseaen
dc.subject5-fluorouracilen
dc.subjectInfluenzaen
dc.subjectColorectal carcinoma advanceden
dc.subjectDry skinen
dc.titlePhase II Study of 5-Fluorouracil and Interferon-Gamma in Patients with Metastatic Colorectal Canceren
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1159/000227553
dc.description.volume53
dc.description.issue2
dc.description.startingpage159
dc.description.endingpage162
dc.author.facultyΙατρική Σχολή / Medical School
dc.author.departmentΙατρική Σχολή / Medical School
dc.type.uhtypeArticleen
dc.contributor.orcidPavlidis, Nicholas [0000-0002-2195-9961]
dc.gnosis.orcid0000-0002-2195-9961


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record